Responses
Oncolytic and local immunotherapy
Original research
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.